Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ASTM $4.20 Aastrom to Hold Annual Meeting of Shareholders on May 7, 2014
http://finance.yahoo.com/news/aastrom-hold-annual-meeting-shareholders-200500713.html
Added TRLPF @.47-.48 in the last
two days. Now averaged @.56
Way oversold here with PDUFA on May 28th.
On February, two of the largest shareholders
bought 14.8 million shares of TRL.TO @.71 ($10.5 million)
and it now trades @.52
Mentioned in an article about testosterone on the
Toronto Life: "In Canada, Eli Lilly is now producing an underarm supplement called Axiron, and Trimel will soon release a gel taken nasally. (Both, say the makers, reduce the risk of cross-contamination.)"
http://www.torontolife.com/style/toronto-health-and-beauty/2014/04/29/youth-in-a-bottle-synthetic-testosterone/
SYN HUGE BEWS OUT ON PERTUSSIS!!:)
Glta Tim
SYN
QRXPY adcom is today and POZN PDUFA on Friday. Not in these
two but good luck to anyone who is in.
TRLPF (.62) - "I like Trimel Pharmaceuticals (TSX:TRL), notwithstanding the selling pressure from its founding shareholder, because it has a better solution for the delivery of a topical treatment of low testosterone in men. The sleeper is that it has the same delivery system for women, where there is a major unmet medical need for female orgasmic disorder."
http://biotuesdays.com/2014/04/01/in-conversation-with-tony-pullen/
"Tony Pullen is one of the deans of Canadian capital markets. His career in biotech traces its roots to 1985 as an advisor to Cangene, which merged with Emergent BioSolutions (NYSE:EBS) in February. He also was instrumental in raising the initial capital for MDS Health Ventures, which went on to become MDS Capital Corp., formerly a leading biotech venture capital firm. In 1991, Mr. Pullen played a leading role in the formation of the biotech technology boutique within Yorkton Securities, which dominated a surge in sector financing until the early 2000s. After a restructuring of Yorkton, Mr. Pullen joined Paradigm Capital as a biotech investment banker and then subsequently left to work on his own with 15 to 20 relationship clients. He continues to work with his clients under the umbrella of D&D Securities. In this interview with BioTuesdays.com, Mr. Pullen reflects on the earlier contraction of the Canadian biotech sector, recent stirrings of a revival and companies with potential for success."
TBUFF (.64) - Up 9% today. Closed position and took
approx 60% profit on my last shares. This one
has been acting very strong during this Biotech
carnage. There was a seeking alpha article
out a few days ago:
http://seekingalpha.com/article/2134083-why-does-this-former-pharma-king-keep-buying-shares-of-tribute-pharmaceuticals
SYN Choo!! Choo!!
All Aboard!
GLTA!
Tim
SYN. Took off late today. $2.55 as typed
SYN had good volume yesterday and had a low of $2.17 and a high of 2.38 13 days until Ph II results on 4-28. Looking for an entry point.
ABIO S-3 filed for $75M.
I really like the consolidation pattern in the weekly chart for ABIO. I'll be looking to take an initial position probably this week and look to add if it can hold the 50sma.
CMXI ONCS CTSO some otc bio are doing ok while most big board bio are in sell-off mode with IBB..
btw, i agree with you on SYN (zero shares currently)
once the IBB stops bleeding, and according to TDAmeritrades charts SYN looks very darn bullish and the buyers might start to come back in. SYN has a Phase II update on 4-28. All reports show positive results.
Do your own DD.
all my posts are lies.
CTSO green now ! looks like stopped bleeding whew!
CTSO $0.21 CytoSorbents to Present at the 13th Annual Needham Healthcare Conference
https://finance.yahoo.com/news/cytosorbents-present-13th-annual-needham-123000303.html
ADMP (6.39) - I really like the potential
here. bought a month ago @6.3 #msg-97623052
New March presentation:
https://docs.google.com/file/d/0Bwgu6jYVrAKiaWFVUWZRdkx4OG1RNldudEY1cS16aE8xS3dj/edit
CRT capital research report:
https://docs.google.com/file/d/0Bwgu6jYVrAKiZDVfRWpPZ2E4b0hOc2p0LUZ5MlA4OFFxM0xj/edit?pli=1
exploded! ASTM
Been eyeing this one for awhile...
TBUFF we had them do a presentation in our paltalk chatroom at the end of February....it was in the .30s then...what a move
QRXPY (4.13) - seekingalpha article out today:
http://seekingalpha.com/article/2102433-qrxpharma-pivotal-catalysts-present-significant-near-term-upside-potential?source=yahoo
QRXPY (3.94) - PDUFA date of 25 May 2014 for action on the Company's refiled New Drug Application for immediate release MOXDUO. The FDA will schedule an Advisory Committee meeting prior to this date (sometime in April).
http://qrxpharma.com/go.cfm?do=Page.View&pid=19
"Pending US approval, we are well prepared and poised to launch MOXDUO in the US with Actavis. Actavis' proven track record in the launching and marketing of opioid products will facilitate rapid uptake and significant sales in the US and maximize value for our shareholders."
"The FDA previously confirmed that the Company’s Combination Rule Trial, Study 008, satisfied efficacy requirements and that there were no efficacy or safety issues identified in any of the studies submitted in the original NDA"
http://qrxpharma.com/download/file/filings/2013/QRxPharma_Resubmits_MoxDuo_IR_NDA_Nov_2013_Final.pdf
March presentation:
http://qrxpharma.com/download/file/cp/QRxPharma_Investor_Deck_March_2014_Final_%2814_March_2014%29.pdf
TRLPF - bought more @.61. After the 1.5 million
block yesterday and Melnyk out of the way, i think the
bottom is in or almost in and the stock will be supported
around this level (the 200 day MA) and will bounce from here.
http://stockcharts.com/h-sc/ui?s=trl.to&p=D&yr=0&mn=9&dy=0&id=p05338879131
My FDA plays are ISR, CVM, ABIO, NAVB
TBUFF (.61) - up another 17% today and 56%
since my original post. Getting way overbought
here so sold some more.
TRLPF - the stock dropped because
Trimel's shareholder Eugene Melnyk has filed a notice of intention to sell two million shares, according to the Toronto Stock Exchange. As in the March 10, 2014, notice, Mr. Melnyk plans to sell the shares privately or through the TSX starting on March 17, 2014. Mr. Melnyk owns 39,110,783 Trimel shares.
Earlier today there was a cross of 1.5 million
shares @.65 and the stock is now up 5% to .74,
so i guess he is out of the way.
trlpf any idea why it dropped yesterday, tempted to pick up some more but difficult to find info. Im in at .70
http://www.trimelpharmaceuticals.com/Portals/0/IR%20-%20%20February%202014.pdf
TBUFF (.52) - up another 10% today and
30% since my original post. Getting a little
overbought here so sold some more today.
TBUFF (.47) - going up slowly in the last
few days with relatively big volume for this stock.
Sold some here.
OXGN was another good one. 160% in 2 weeks.
From $2 #msg-97962677 to $5.3 today #msg-98669854
Phase 2 results were out yesterday:
http://finance.yahoo.com/news/oxigene-announces-positive-topline-results-193553328.html
There are a lot of good opportunities with
biotech stocks.
WMGIZ is a great FDA play, imo. FDA Dispute Resolution Panel is likely better odds of approval of Augment as opposed to traditional FDA Appeal Process. Approval Milestone ($3.50) expires ~ 5 years, and that is a long time for things to materialize. The entire Company / Augment Department could be merged / sold off. Even without approval of Augment in US within 5 years, the revenue milestone payout(s) of $3.00 is a very likely outcome as Augment is being marketed in foreign markets. Please do your own due diligence and this is all in my own opinion. Good luck out there!
Re: NRIFF, i posted on it @1.7 #msg-94784723
and it tripled in 5 weeks #msg-96056362
I did we'll on nrif Canadian pdufa play. Will checkmout
TRLPF – bought @.67. They have a PDUFA on May 28th for
CompleoTRT , a testosterone replacement therapy.
They decided, following discussions with the FDA, to focus its CompleoTRT regulatory
submission on a three times a day and not twice a day dosing schedule.
This pushed the PDUFA date to May 28th (from February 28th).
Trimel also recently completed recruitment for the 240-patient, Tefina ambulatory Phase II study in
anorgasmia/female orgasmic disorder. Results should be out in Q214.
A few days ago they raised $10.5 million from current shareholders at market price:
http://finance.yahoo.com/news/trimel-announces-10-5-million-203753113.html
Trades in Canada as TRL.TO. 163 million OS shares.
Some of the people involved with TRL were also involved with Biovail (merged with Valeant and trades
as VRX on the NYSE).
February 2014 presentation:
http://www.trimelpharmaceuticals.com/Portals/0/IR%20-%20%20February%202014.pdf
Aezs shelf filing. 250,000,000. Not sure if its worth letting my capitlaln sit here now
In Stunning Win For Open Science, Johnson & Johnson Decides To Release Its Clinical Trial Data To Researchers
Drug companies tend to be secretive, to say the least, about studies of their medicines. For years, negative trials would not even be published. Except for the U.S. Food and Drug Administration, nobody got to look at the raw information behind those studies. The medical data behind important drugs, devices, and other products was kept shrouded.
Today, Johnson & Johnson JNJ -1.33% is taking a major step toward changing that, not only for drugs like the blood thinner Xarelto or prostate cancer pill Zytiga but also for the artificial hips and knees made for its orthopedics division or even consumer products. “You want to know about Listerine trials? They’ll have it,” says Harlan Krumholz of Yale University, who is overseeing the group that will release the data to researchers.
“We really wanted a broad approach to contributing to advancing medical science through all of our products that touch patients in different ways,” says Joanne Waldstreicher, MD, Chief Medical Officer, Johnson & Johnson. “Responsible sharing of clinical trial data advances science and medicine and is part of Johnson & Johnson’s commitment to the doctors, nurses, patients, mothers, and fathers and all others who use our products,” said Paul Stoffels, MD, J&J’s chief scientific officer, in a prepared statement.
Here’s how the process will work: J&J has enlisted The Yale School of Medicine’s Open Data Access Project (YODA) to review requests from physicians to obtain data from J&J products. Initially, this will only include products from the drug division, but it will expand to include devices and consumer products. If YODA approves a request, raw, anonymized data will be provided to the physician. That includes not just the results of a study, but the results collected for each patient who volunteered for it with identifying information removed. That will allow researchers to re-analyze or combine that data in ways that would not have been previously possible.
Waldstreicher admits that there will be “a bit of a learning process.” What, for instance, about data from trials for rare diseases, where it may be possible to figure out who the participants were? Or what if the data is held not by J&J, but by a partner? But she commits to trying to get the data released even in those cases if it is feasible.
Krumholz, who heads the YODA Project, says that he hopes J&J’s leadership will set “a remarkable standard for data sharing that will ripple not only through industry but also through academia.” He hopes it will help the company by teaching them more about their drugs. “They’re going to get peoplelooking at their data for free.”
This is not the first time that a drug company has offered to make this type of raw, or patient-level, data public. GlaxoSmithKline GSK -2.29% has made big promises about doing something similar, although it is choosing its own review board to get data released. Medtronic MDT -1.28% worked on a similar project with YODA, but only for a single, controversial product, the bone drug INFUSE.
Scientists can make a request for data on J&J drugs by going to www.clinicaltrialstudytransparency.com.
http://health.einnews.com/article/188032375
Aezs 1.28 May add if it drops more w/ the market on Monday.
Chtp if no delay by end next week watch this start to move. Still think there will be buying opportunity this week.
Vnda pdufa date 1-31-14. Do not expect any great gains because approval may b factored in somewhat. Looking to enter low 13's tomorrow and sell high 15's on approval
Igxt- finally gonna break. .74 on to ifs run up to Feb Pfufa date .. will sell most of my shares b4 if not all.
Aezs. - good z to buy in and just let money sit for 9 months ..easy 3 bagger if u don't need the capital.
TBUFF (0.39) – Tribute Pharmaceuticals is an emerging Canadian specialty pharmaceutical company with a primary focus
on the acquisition, licensing, development and promotion of healthcare products in Canada.
Market Cap: $20M OS Shares: 51.0M
TBUFF has an experienced management team and board, which includes John Gregory who Founded and built King Pharmaceuticals (formerly NYSE:KG) which was sold to Pfizer for $3.6 billion. He is managing partner of SJ Strategic Investments, a family owned investment management firm. Mr. Gregory owns 16% of Tribute.
Robert Harris the President & CEO held executive positions at Biovail Corporation including VP of Business Development and GM of Biovail’s Canadian commercial group ,where he helped grow revenues to $150M within four years, leading to Biovail’s acquisition by Valeant (NYSE:VRX) for $3.2 billion. 20 years at Wyeth, now division of Pfizer (NYSE:PFE),where as Director of Sales of Specialty Care group he built out Canadian market segment.
Insider Ownership: 57%
Insiders bought in 2013 @.40 - .56:
http://finance.yahoo.com/q/it?s=TBUFF+Insider+Transactions
Tribute Pharmaceuticals Canada Inc.’s current portfolio of assets includes nine products: NeoVisc®, NeoVisc® Single Dose, Uracyst®, BladderChek®, Bezalip® SR, Soriatane®, Cambia®, Daraprim®, Collatamp G® and MycoVa™. Each of these products has received regulatory approval in Canada, with the exception of MycoVa.
TBUFF sells Cambia for acute migraine, in Canada. The medication is sold in a sachet form, a powder mixed with a couple of ounces of water. It is extremely fast acting. Nautilus Neurosciences has licensed Cambia to TBUFF.
A month ago, Depomed acquired Cambia US rights from Nautilus for $49 million:
http://finance.yahoo.com/news/depomed-acquires-cambia-diclofenac-potassium-210500674.html
http://finance.yahoo.com/news/cambia-r-tribute-pharmaceuticals-130000063.html
Another Tribute product is called Bezalip SR which is a fibrate drug intended to lower cholesterol. TBUFF acquired the license to sell the drug in Canada. The company also owns the license to sell Bezalip in the U.S.and filed an IND with the FDA in November:
http://finance.yahoo.com/news/tribute-pharmas-investigational-drug-application-130000337.html
Presentation:
http://content.stockpr.com/tributepharma/media/0a26f60f9fe2b220d091c62d6123d81e.pdf
This might be interesting here being so close to breaking above the 50 and 200 day MA @.39 & .42 respectively.
$ADMD News>
Advanced Medical Isotope Corporation Announces Three Year Business Strategy Focused on Transitioning From a Development-Stage Company to an Operating Company
Operations to Center on Yttrium-90 Brachytherapy Products Following Anticipated Receipt of FDA Clearance of Y-90 RadioGel(TM) Brachytherapy Device
KENNEWICK, Wash., Dec 02, 2013 (GLOBE NEWSWIRE via COMTEX) -- Advanced Medical Isotope Corporation ("AMIC") (OTCBB:ADMD), a company engaged in the development, production and distribution of medical isotopes, today announced that its Board of Directors has approved a three year business strategy focused on transitioning to full operations in 2014, following the anticipated receipt of FDA clearance for its patented brachytherapy cancer product, Yttrium-90 RadioGel.
The business strategy results from the Company's success in developing a family of three brachytherapy devices and the Company's belief that there is: (1) strong market potential for these products in the United States and internationally, (2) the potential for attractive operating margins from the commercialization of such devices, (3) a considerably smaller capital requirement to complete the regulatory process and deploy these devices, as compared to the capital required for most of the other initiatives the Company is developing and (4) a material potential for the Company to receive advances and minimum guarantees from international licensees of these products.
The business strategy recognizes the advanced stage of development for certain other Company initiatives and prioritizes those initiatives based upon criteria, including: capital requirements and sources; market size and operating margin; competition and strength of AMIC's intellectual property protection; probability of implementation; and support for the Company's immediate goal of deploying its brachytherapy products upon receipt of regulatory approval and sufficient financing.
The Company's financing efforts, allocation of resources, participation in industry events, web site and other activities will be modified to implement the priorities adopted by the Board.
AMIC To Focus on Launch of Yttrium-90 Brachytherapy Products
AMIC announced on November 3, 2013 that it filed a premarket notification with the U.S. Food and Drug Administration (FDA) pursuant to section 510(k) for a patented brachytherapy cancer treatment using the Yttrium-90 (Y-90) RadioGel device. On November 18, 2013, the FDA notified AMIC that an administrative acceptance review was conducted and the Company's premarket notification was found to contain all of the necessary elements and information needed to proceed with the substantive review. Pursuant to Section 510(k), the FDA has until approximately February 2014 in which to clear AMIC's Yttrium-90 RadioGeldevice for commercial distribution or to seek additional information. The FDA previously confirmed that it would review the product as a medical device. Following notification of FDA clearance, the Company would immediately have the right to commence manufacturing, marketing and sales of the product in the United States and its possessions.
The Company intends to file FDA premarket notifications for two related Yttrium-90 brachytherapy devices promptly after receiving either clearance from the FDA for the Y-90 RadioGel device, or any comments from the FDA to its application.
Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. Annual sales of brachytherapy products exceed $1 billion, about half of which are in the United States. Among the cancers for which brachytherapy is often selected as a treatment are prostate, liver, breast, as well as head and neck tumors. AMIC's products may also offer treatment options for certain pancreatic cancers. Once it receives FDA clearance, AMIC intends to begin marketing efforts in the United States for its Y-90 RadioGel(TM) device. In addition, AMIC intends to seek opportunities to license its products for worldwide sales, subject to the applicable local regulatory approvals.
The composition and uses of AMIC's brachytherapy products are protected by a series of exclusive patent licenses from the Battelle Memorial Institute and the University of Utah.
The three Y-90 brachytherapy devices developed by AMIC are:
- Y-90 RadioGel Device - combines insoluble Y-90 microspheres and a polymer carrier that is injected directly into the tumor;
- Y-90 Fast-Resorbable Polymer Seeds - intended as a safer, more effective and less expensive alternative to existing metal and glass seeds used in other brachytherapy devices;
- Y-90 Polymer Topical Paste - intended as a supplemental treatment to be applied into a surgical incision to kill residual tumor cells.
As noted above, the 510(k) application filed by AMIC pertains only to the Y-90 RadioGel device.
AMIC's analyses support an expectation that its brachytherapy products will achieve a higher therapeutic index than existing brachytherapy products, while reducing collateral damage to healthy tissue due to the shorter penetration distance, shorter half-life and other attributes of the device as compared to brachytherapy devices that use isotopes emitting gamma radiation. These features also reduce the risk of radiation exposure to the patient, family members and medical personnel involved in manufacturing and injecting the device. In addition, the AMIC Y-90 RadioGel device uses a biodegradable carrier with FDA approved components which leaves no metal or glass in the patient.
In the United States, the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the United States, the Company intends generally to enter into licensing arrangements. The Company will evaluate its alternatives before finalizing its plans.
AMIC also to Expand Sales Capability and Consider Acquisition of German Company
The Board approved of two secondary priorities for 2014 and 2015:
-- Expansion of the Company's sales agency activities for isotopes and related equipment manufactured by third parties. This activity requires very little capital, facilitates the Company's interaction with potential partners, customers and vendors and should be immediately cash positive. In the third quarter of 2013, the Company derived approximately $115,000 from such activities. By expanding this activity, the Company expects to be able to raise less capital through the sale of securities, thereby reducing dilution for shareholders. Profits from sales agency activities also could help create greater shareholder value, particularly if the Company is valued based upon its core brachytherapy business.
-- Potential acquisition of a controlling interest in a specific company headquartered in Germany with which AMIC has been cooperating for the last few years. Acquisition of a controlling interest in this company could facilitate the Company's business progress in Germany and other European markets. Germany accounts for the largest market share of the European nuclear medicine market, which is the world's second-largest market for nuclear medicine, after the United States. The target company presently derives less than 1% of its sales in the United States. AMIC believes it could contribute to a significant increase in U.S. sales for this target company.
Although the parties have reached an agreement in principle on a path forward, any transaction would be subject to reaching definitive agreements, AMIC obtaining sufficient financing and any required regulatory approvals. Because the target company is fully-operational and profitable, a business combination likely would be immediately accretive for AMIC shareholders.
The Board's business strategy also contemplates that the Company will continue operation of its linear accelerator located in Kennewick, consider building a larger cyclotron production facility in Southern California in partnership with a major medical facility and continue its research and development activities for other isotopes and technologies, though the pace of all activities will be subject to the needs and performance of the Company's strategic priorities, particularly the successful launch and growth of the brachytherapy products.
AMIC's Financial Requirements and Prospects
Over the next year, the Company anticipates a requirement of about $1.5 million to maintain current operating activities and from approximately $2 million to $5 million to fund: (1) the FDA approval process and initial deployment of the brachytherapy products, and (2) a sales capability for third party isotopes and equipment. The continued deployment of the brachytherapy products would require additional spending. The principal variable in the amount of near-term spending for the brachytherapy products will be the nature of the Company's arrangements with third parties for manufacturing, sales, distribution and licensing of those products.
The acquisition of a controlling interest in the German company likely would require up to approximately $3 million of cash and stock. Following its acquisition, the target company should operate on a cash positive basis. In allocating its capital between the brachytherapy products and the potential acquisition, the Company's first priority is the FDA clearance for, and successful roll-out of, the brachytherapy products. The Company believes that its acquisition of a controlling interest in the German target company would help achieve that goal in Europe and Russia.
The Company anticipates funding the initial six months of its requirements for brachytherapy, sales agency activities and potentially the acquisition of a controlling interest in the German company through the sale of equity or equity-linked securities. In support of these efforts, the Company has reached an agreement in principle with the Company's largest creditors to convert most of their debt into equity concurrent with the Company's receipt of funds on pricing comparable to that obtained in any such financings.
Thereafter, the Company anticipates that funding also would be provided by the Company's business activities, including, potentially, advances from foreign licensees for the brachytherapy products and proceeds from the sales agency activities and the Company's linear accelerator in Kennewick.
There can be no assurance regarding the outcome of the Company's regulatory, financing or commercial efforts. If some of the anticipated results are delayed or do not occur, the Company's anticipated spending and capability to fund that spending would decline. Conversely, if the Company has the financial capacity to do so, the Company could spend additional sums to grow its businesses more rapidly and to maintain or accelerate research and development activities for future products and technologies.
Though there are many uncertainties, if the FDA provides clearance for the RadioGel device during the first half of 2014, the Company believes that its operations could turn cash-positive within four to nine months thereafter and could turn profitable on a GAAP-basis within six to 12 months after clearance is obtained, in each instance despite increased spending to support the deployment.
To bolster its capability to seek funding and to structure and negotiate outsourcing and licensing agreements, in October 2013, the Board elected Kenin M. Spivak to be a Director and Vice-Chairman. Mr. Spivak has extensive experience securing, structuring and negotiating complex transactions, including financings, manufacturing, sales, marketing, distribution, licensing, joint ventures and business combinations and directing roll-outs for a range of technologies, products and services. Though Mr. Spivak will not be a full-time Company officer or direct the Company's roll-out of its brachytherapy products, the Company believes that Mr. Spivak's advice and support will materially benefit the Company's effort.
If the Company obtains the financing it seeks, the Company anticipates that it will be able to employ more of its part-time scientists on a full-time basis and that it will be able to engage marketing professionals with experience directly pertinent to its brachytherapy products.
AMIC's Longer-Term Business Strategy
The business strategy adopted by the Board mandates that the Company's first priority after 2015 would continue to be the deployment of its brachytherapy devices. Second, the Company would continue to nurture and grow the other business activities undertaken in 2014 and 2015. Subject to the success of the Company's business and the availability of sufficient resources, by 2016, the Board has directed that the Company take steps toward the commercialization of other isotopes, businesses and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses.
Among those longer-term projects being considered by the Company are potential solutions for the impending severe shortages of Molybendum-99 and its derivative product Technetium-99m, the most widely used isotopes for diagnostic purposes.
Conclusions
AMIC Founder, Chairman and CEO James C. Katzaroff commented: "The business strategy mandated by the Board is intended to focus AMIC on smoothly and profitably transitioning from a development-stage company into an operating company with a series of products that will help improve lives, can be commercially introduced with limited capital requirements and can reach positive cash flow and profits within a reasonable period after we receive clearance from the FDA."
Mr. Katzaroff added: "Though AMIC will continue to progress our growth as a sales agency and will continue discussions for a possible acquisition in Europe, we will do so in support of our core mission to obtain FDA clearance and funding for our RadioGel(TM) device and other brachytherapy products so that we can commercially roll out these products commencing in 2014. We also will continue discussions for a cyclotron production facility and development of other products and technologies. However, the resources allocated to all AMIC activities will now be assessed against the impact on a successful deployment of our brachytherapy products and using that deployment to deliver therapeutic value to patients and financial value for our shareholders."
About Advanced Medical Isotope Corporation
Advanced Medical Isotope Corporation (OTCBB:ADMD) is a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications. AMIC's focus is on transitioning to full operations upon receipt of expected FDA clearance for its patented brachytherapy cancer product, Yttrium-90 RadioGel. AMIC intends to file FDA premarket notifications for two related Yttrium-90 brachytherapy products. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. Annual sales of brachytherapy products exceed $1 billion, about half of which are in the United States. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our website, www.isotopeworld.com.
The Advanced Medical Isotope Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5139
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, AMIC's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
CONTACT: Advanced Medical Isotope Corporation
James C. Katzaroff
(509) 736-4000
6208 W. Okanogan Ave.
Kennewick, WA 99336
http://media.globenewswire.com/cache/7035/small/5741.jpg
(Logo: http://media.primezone.com/cache/7035/int/5741.jpg)
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwNTk5MjUjNzAzNQ==
(C) Copyright 2013 GlobeNewswire, Inc. All rights reserved.
-0-
KEYWORD: KENNEWICK, Wash.
INDUSTRY KEYWORD: Medical Supplies
SUBJECT CODE: Company Announcement
MEDICAL
HEALTH
Does anyone remember
Vermillion Inc (VRML.W)
About 4 years ago it went from 3 cents to 38 bucks in less than 5 days.Everything about $ADMD feels the exact same way.If we get FDA approval.(we will fly) Go $ADMD
~ HALO.. huge congrats to captain io_io of pirate ship and his crew members since HALO was your strong strong pick for over the year!!!..you posted your dd(s) after dd(s) there... i couldn't understand well since it looked too difficult for me...
well, i knew the pps would spike after i'm stopped out the other day...
,,,except a few bio-stocks, i placed stops and my HALO was gone...its not all my fault though since at that time, bio market looked very crazy!
is it still ok for me to get back in here...? ...hahaha
~ dumb,,,why did i place the stops on HALO... sometimes, i really hate myself on trading these bio.... btw, i love my CHTP...i know you posted several dd(s) there but was it your pick also? (sorry, i forgot)
where did everyone go? how bout ZLCS?? 2 catalysts late Oct/Nov + ODD designation
NVAX - 9/24 is 1st ever analyst day. if anything surprising positive, this will gap up the stock. otherwise, i think low $3s is fair for now.
Followers
|
566
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
24568
|
Created
|
09/18/09
|
Type
|
Free
|
Moderator cccpmd666 | |||
Assistants Guy colorofmoney |
Posts Today
|
0
|
Posts (Total)
|
24568
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |